Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Semin Respir Crit Care Med. 2013 Oct;34(5):600-19. doi: 10.1055/s-0033-1356548. Epub 2013 Sep 13.
Pulmonary hypertension (PH) may complicate parenchymal lung disease, specifically interstitial lung diseases and chronic obstructive pulmonary disease, and uniformly increases the mortality risk. The epidemiology and degree of PH is variable and unique to the underlying lung disease. The clinician should exercise a high index of suspicion for PH complicating parenchymal lung disease especially given the nonspecific symptomatology and the limitations of echocardiography in this patient population. In general, PH-specific therapies in this setting have been poorly studied, with concern for increased shunting and/or ventilation/perfusion (V/Q) mismatch and resultant hypoxemia. A better understanding of the mechanisms underlying PH related to parenchymal lung disease may lead to novel pharmacological targets to prevent or treat this serious complication.
肺高血压（PH）可能使实质肺疾病，特别是间质性肺疾病和慢性阻塞性肺疾病复杂化，并普遍增加死亡风险。PH 的流行病学和严重程度因基础肺病而异，具有独特性。鉴于该患者人群中超声心动图的非特异性症状和局限性，临床医生应该对实质肺疾病并发 PH 保持高度怀疑。一般来说，特定于 PH 的治疗在这种情况下研究甚少，这与增加的分流和/或通气/灌注（V/Q）不匹配以及由此导致的低氧血症有关。对与实质肺疾病相关的 PH 的潜在机制的更好理解可能会导致预防或治疗这种严重并发症的新的药理学靶点。
